Linaglip M 2.5/850 mg

Linaglip-M 2.5/850 mg is an oral anti-diabetic medication that combines Linagliptin (2.5 mg) and Metformin Hydrochloride (850 mg). It helps control blood sugar levels in patients with Type 2 Diabetes Mellitus by improving insulin sensitivity, reducing glucose production, and enhancing incretin hormone activity.

Ingredients:
Linagliptin (2.5 mg) – A DPP-4 inhibitor that enhances incretin function.
Metformin Hydrochloride (850 mg) – A biguanide that reduces glucose production and improves insulin sensitivity.

Direction of Use:
Take with meals to reduce gastrointestinal side effects.
Swallow whole with water; do not crush or chew.
Follow the dosage as prescribed by the doctor.

Indication:
Used for Type 2 Diabetes Mellitus when diet and exercise alone are insufficient to control blood sugar levels.
Can be used as monotherapy or in combination with other anti-diabetic drugs.

Pharmacology, Dosage & Administration:
Pharmacology:
Linagliptin increases insulin secretion and decreases glucagon release.
Metformin reduces hepatic glucose production and increases peripheral glucose uptake.

Dosage & Administration:
The usual starting dose is one tablet twice daily with meals.
Dosage adjustments should be based on the patient’s response and kidney function.

Interaction:
May interact with insulin, sulfonylureas, diuretics, corticosteroids, and beta-blockers.
Alcohol may increase the risk of lactic acidosis with metformin.

Contraindications:
Severe renal impairment (eGFR <30 mL/min/1.73m²).
Metabolic acidosis, including diabetic ketoacidosis.
Known hypersensitivity to any component.

Side Effects:
Common: Nausea, diarrhea, abdominal discomfort, headache.
Serious: Lactic acidosis (rare but life-threatening), hypoglycemia (when combined with insulin or sulfonylureas).

Precautions & Warnings:
Monitor renal function regularly.
Use cautiously in elderly patients and those with liver disease or heart failure.
Stop temporarily before contrast imaging procedures to avoid kidney damage.

Overdose Effects:
Metformin overdose may cause lactic acidosis (seek immediate medical attention).
Linagliptin overdose may lead to hypoglycemia, especially when combined with other anti-diabetics.

Therapeutic Class:
Dipeptidyl Peptidase-4 (DPP-4) Inhibitor & Biguanide Combination

Storage Conditions:
Store at room temperature (15–30°C), away from moisture and direct sunlight.
Keep out of reach of children.